{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:26Z","timestamp":1792887806065,"version":"4.5.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    With the advent of survival motor neuron (SMN)-enhancing therapies, the natural course of spinal muscular atrophy (SMA) has been reshaped, unveiling new patient phenotypes. As therapeutic options expand, there is an increasing demand for robust biomarkers to enhance prognostic accuracy, anticipate treatment response, track disease progression, and support personalized clinical decision-making. This narrative review critically examines the literature and discusses the role and appropriate application of key biomarkers across different age groups, ranging from presymptomatic newborns to adults with chronic disease. Genetic testing remains the diagnostic gold standard, with\n                    <jats:italic>SMN2<\/jats:italic>\n                    copy number serving as the strongest prognostic indicator. However, substantial phenotypic variability exists among individuals with the same\n                    <jats:italic>SMN2<\/jats:italic>\n                    copy number. Neurophysiological measures, including compound muscle action potential (CMAP) and motor unit number estimation (MUNE), accurately inform about motor neuron integrity, often anticipating clinical changes and potentially predicting treatment responsiveness. Circulating neurofilaments (NF) are increasingly recognized as sensitive biomarkers of active neurodegeneration. While NF holds promise in infants and younger children, its relevance in adolescents and adults remains limited. Conversely, quantitative muscle imaging techniques, such as MRI and ultrasound, may be valuable tools in adolescent and adult patients, capturing long-term muscle structural changes. By reviewing the current evidence across age groups, we provide an overview of biomarker application in newborns, children and adolescents\/adults for diagnostic, prognostic, predictive, and monitoring purposes to help advance individualized management across all SMA stages.\n                  <\/jats:p>","DOI":"10.1007\/s00415-025-13314-7","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T12:23:45Z","timestamp":1756815825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-969X","authenticated-orcid":false,"given":"Stefania","family":"Corti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ottoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Sansone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"13314_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D'Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E (2011) Spinal muscular atrophy. Orphanet J Rare Dis 6:71. https:\/\/doi.org\/10.1186\/1750-1172-6-71","journal-title":"Orphanet J Rare Dis"},{"key":"13314_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS (2022) Spinal muscular atrophy. Nat Rev Dis Primers 8:52. https:\/\/doi.org\/10.1038\/s41572-022-00380-8","journal-title":"Nat Rev Dis Primers"},{"key":"13314_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Le Paslier D, Fr\u00e9zal J, Cohen D, Weissenbach J, Munnich A, Melki J (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155\u2013165. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3","journal-title":"Cell"},{"issue":"7","key":"13314_CR4","doi-asserted-by":"publisher","first-page":"7S15","DOI":"10.1016\/S0929-693X(20)30271-2","volume":"27","author":"F Audic","year":"2020","unstructured":"Audic F, Barnerias C (2020) Spinal muscular atrophy (SMA) type I (Werdnig-Hoffmann disease). Arch Pediatr 27(7):7S15-7S17. https:\/\/doi.org\/10.1016\/S0929-693X(20)30271-2","journal-title":"Arch Pediatr"},{"key":"13314_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","volume":"51","author":"WD Arnold","year":"2015","unstructured":"Arnold WD, Kassar D, Kissel JT (2015) Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 51:157\u2013167. https:\/\/doi.org\/10.1002\/mus.24497","journal-title":"Muscle Nerve"},{"key":"13314_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/archneurol.2010.373","volume":"68","author":"P Kaufmann","year":"2011","unstructured":"Kaufmann P (2011) Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol 68:779. https:\/\/doi.org\/10.1001\/archneurol.2010.373","journal-title":"Arch Neurol"},{"key":"13314_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S et al (2018) Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28:103\u2013115. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005","journal-title":"Neuromuscul Disord"},{"key":"13314_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1750-3639.2001.tb00395.x","volume":"11","author":"H Schmalbruch","year":"2001","unstructured":"Schmalbruch H, Haase G (2001) Spinal muscular atrophy: present state. Brain Pathol 11:231\u2013247. https:\/\/doi.org\/10.1111\/j.1750-3639.2001.tb00395.x","journal-title":"Brain Pathol"},{"key":"13314_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/jpm10030075","volume":"10","author":"P Smeriglio","year":"2020","unstructured":"Smeriglio P, Langard P, Querin G, Biferi MG (2020) The identification of novel biomarkers is required to improve adult SMA patient stratification, diagnosis and treatment. J Pers Med 10:75. https:\/\/doi.org\/10.3390\/jpm10030075","journal-title":"J Pers Med"},{"key":"13314_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030417","volume":"11","author":"T Aslesh","year":"2022","unstructured":"Aslesh T, Yokota T (2022) Restoring SMN expression: an overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells 11:417. https:\/\/doi.org\/10.3390\/cells11030417","journal-title":"Cells"},{"key":"13314_CR11","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 96:6307\u20136311. https:\/\/doi.org\/10.1073\/pnas.96.11.6307","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13314_CR12","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani UR (1999) A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8:1177\u20131183. https:\/\/doi.org\/10.1093\/hmg\/8.7.1177","journal-title":"Hum Mol Genet"},{"key":"13314_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldk\u00f6tter","year":"2002","unstructured":"Feldk\u00f6tter M, Schwarzer V, Wirth R, Wienker TF, Wirth B (2002) Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70:358\u2013368. https:\/\/doi.org\/10.1086\/338627","journal-title":"Am J Hum Genet"},{"key":"13314_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2016.00007","volume":"3","author":"MER Butchbach","year":"2016","unstructured":"Butchbach MER (2016) Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosci 3:7. https:\/\/doi.org\/10.3389\/fmolb.2016.00007","journal-title":"Front Mol Biosci"},{"key":"13314_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Nusinersen: first global approval. Drugs 77:473\u2013479. https:\/\/doi.org\/10.1007\/s40265-017-0711-7","journal-title":"Drugs"},{"key":"13314_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM (2019) Onasemnogene abeparvovec: first global approval. Drugs 79:1255\u20131262. https:\/\/doi.org\/10.1007\/s40265-019-01162-5","journal-title":"Drugs"},{"key":"13314_CR17","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Risdiplam: first approval. Drugs 80:1853\u20131858. https:\/\/doi.org\/10.1007\/s40265-020-01410-z","journal-title":"Drugs"},{"key":"13314_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2017.0665","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A (2017) FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther 27:67\u201369. https:\/\/doi.org\/10.1089\/nat.2017.0665","journal-title":"Nucleic Acid Ther"},{"key":"13314_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093297","volume":"21","author":"TH Chen","year":"2020","unstructured":"Chen TH (2020) New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand? Int J Mol Sci 21:3297. https:\/\/doi.org\/10.3390\/ijms21093297","journal-title":"Int J Mol Sci"},{"issue":"8","key":"13314_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/genes15080999","volume":"15","author":"US Haque","year":"2024","unstructured":"Haque US, Yokota T (2024) Recent progress in gene-targeting therapies for spinal muscular atrophy: promises and challenges. Genes 15(8):999. https:\/\/doi.org\/10.3390\/genes15080999","journal-title":"Genes"},{"key":"13314_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/ijns10030056","volume":"10","author":"K Cooper","year":"2024","unstructured":"Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, McNeill A, Bessey A (2024) Systematic review of presymptomatic treatment for spinal muscular atrophy. Int J Neonatal Screen 10:56. https:\/\/doi.org\/10.3390\/ijns10030056","journal-title":"Int J Neonatal Screen"},{"key":"13314_CR22","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41591-022-01889-x","volume":"28","author":"CJ Sumner","year":"2022","unstructured":"Sumner CJ, Crawford TO (2022) Early treatment is a lifeline for infants with SMA. Nat Med 28:1348\u20131349. https:\/\/doi.org\/10.1038\/s41591-022-01889-x","journal-title":"Nat Med"},{"key":"13314_CR23","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40120-024-00653-2","volume":"13","author":"T Hagenacker","year":"2024","unstructured":"Hagenacker T, Maggi L, Coratti G, Youn B, Raynaud S, Paradis AD, Mercuri E (2024) Effectiveness of nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis. Neurol Ther 13:1483\u20131504. https:\/\/doi.org\/10.1007\/s40120-024-00653-2","journal-title":"Neurol Ther"},{"key":"13314_CR24","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, Grandis M, Trojsi F, Cerri F, Ferraro M, Bozzoni V, Caumo L, Piras R, Tanel R, Saccani E, Meneri M, Vacchiano V, Ricci G, Soraru\u2019 G, D\u2019Errico E et al (2020) Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91:1166\u20131174. https:\/\/doi.org\/10.1136\/jnnp-2020-323822","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13314_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","volume":"39","author":"J Erdos","year":"2022","unstructured":"Erdos J, Wild C (2022) Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. Eur J Paediatr Neurol 39:1\u201310. https:\/\/doi.org\/10.1016\/j.ejpn.2022.04.006","journal-title":"Eur J Paediatr Neurol"},{"key":"13314_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dmcn.14027","volume":"61","author":"T Gidaro","year":"2019","unstructured":"Gidaro T, Servais L (2019) Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol 61:19\u201324. https:\/\/doi.org\/10.1111\/dmcn.14027","journal-title":"Dev Med Child Neurol"},{"key":"13314_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejpn.2024.06.001","volume":"51","author":"J Kirschner","year":"2024","unstructured":"Kirschner J, Bernert G, Butoianu N, De Waele L, Fattal-Valevski A, Haberlova J, Moreno T, Klein A, Kostera-Pruszczyk A, Mercuri E, Quijano-Roy S, Sejersen T, Tizzano EF, Van Der Pol WL, Wallace S, Zafeiriou D, Ziegler A, Muntoni F, Servais L (2024) 2024 update: European consensus statement on gene therapy for spinal muscular atrophy. Eur J Paediatr Neurol 51:73\u201378. https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.001","journal-title":"Eur J Paediatr Neurol"},{"key":"13314_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2021.100899","volume":"38","author":"RJ Butterfield","year":"2021","unstructured":"Butterfield RJ (2021) Spinal muscular atrophy treatments, newborn screening, and the creation of a neurogenetics urgency. Semin Pediatr Neurol 38:100899. https:\/\/doi.org\/10.1016\/j.spen.2021.100899","journal-title":"Semin Pediatr Neurol"},{"key":"13314_CR29","doi-asserted-by":"publisher","first-page":"e200310","DOI":"10.1212\/CPJ.0000000000200310","volume":"14","author":"M Schroth","year":"2024","unstructured":"Schroth M, Deans J, Arya K, Castro DC, De Vivo DC, Gibbons MA, Ionita C, Kuntz NL, Lakhotia A, Neil Knierbein E, Scoto M, Sejersen T, Servais L, Tian C, Waldrop MA, V\u00e1zquez-Costa JF (2024) Spinal muscular atrophy update in best practices: recommendations for diagnosis considerations. Neurol Clin Pract 14:e200310. https:\/\/doi.org\/10.1212\/CPJ.0000000000200310","journal-title":"Neurol Clin Pract"},{"key":"13314_CR30","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/neurolint16060096","volume":"16","author":"A Lemska","year":"2024","unstructured":"Lemska A, Ruminski P, Szymarek J, Studzinska S, Mazurkiewicz-Beldzinska M (2024) Efficacy of nusinersen treatment in type 1, 2, and 3 spinal muscular atrophy: real-world data from a single-center study. Neurol Int 16:1266\u20131278. https:\/\/doi.org\/10.3390\/neurolint16060096","journal-title":"Neurol Int"},{"key":"13314_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41434-022-00349-y","volume":"30","author":"A Reilly","year":"2023","unstructured":"Reilly A, Chehade L, Kothary R (2023) Curing SMA: are we there yet? Gene Ther 30:8\u201317. https:\/\/doi.org\/10.1038\/s41434-022-00349-y","journal-title":"Gene Ther"},{"key":"13314_CR32","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1007\/s00431-023-04883-8","volume":"182","author":"L Antonaci","year":"2023","unstructured":"Antonaci L, Pera MC, Mercuri E (2023) New therapies for spinal muscular atrophy: where we stand and what is next. Eur J Pediatr 182:2935\u20132942. https:\/\/doi.org\/10.1007\/s00431-023-04883-8","journal-title":"Eur J Pediatr"},{"key":"13314_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R, Schreiber-Katz O, Osmanovic A, Petri S, Kizina K, Zange J, Koch JC, Schilling M, Steinbach R, Fuss S, Nobile T, Wolf T, Ludolph AC, Otto M, Dabbous O, Meyer T (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 19:317\u2013325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30037-5","journal-title":"Lancet Neurol"},{"key":"13314_CR34","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","volume":"11","author":"T Duong","year":"2021","unstructured":"Duong T, Wolford C, McDermott MP, Quigley J, Chen L, McGraw S, Martens WB, Chung WK, Ferguson ML, Day JW, Tawil R, Pasternak A, Sproule DM (2021) Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract 11:e317\u2013e327. https:\/\/doi.org\/10.1212\/CPJ.0000000000001033","journal-title":"Neurol Clin Pract"},{"key":"13314_CR35","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, ENDEAR Study Group (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"key":"13314_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","volume":"68","author":"TO Crawford","year":"2023","unstructured":"Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, Kirschner J, Kuntz NL, Nazario AN, Parsons JA, Pechmann A, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Zhu C, Raynaud S, Lago TR, Paradis AD, Foster R, Chin R, Berger Z, NURTURE Study Group (2023) Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve 68:157\u2013170. https:\/\/doi.org\/10.1002\/mus.27853","journal-title":"Muscle Nerve"},{"key":"13314_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, Xiong H, Zanoteli E, Baranello G, Bruno C, Vlodavets D, Wang Y, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Fontoura P, Servais L, FIREFISH Working Group (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385:427\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa2102047","journal-title":"N Engl J Med"},{"key":"13314_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, Vuillerot C, Baranello G, Boespflug-Tanguy O, Goemans N, Kirschner J, Kostera-Pruszczyk A, Servais L, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Staunton H, Yeung WY, Martin C, Fontoura P, Day JW, SUNFISH Study Group (2022) Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo- controlled trial. Lancet Neurol 21:42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7","journal-title":"Lancet Neurol"},{"key":"13314_CR39","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, Reash NF, Iammarino MA, Church KR, Kleyn A, Meriggioli MN, Shell R (2021) Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol 78:834\u2013841. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1272","journal-title":"JAMA Neurol"},{"key":"13314_CR40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, Iannaccone ST, Kuntz NL, Pe\u00f1a LDM, Shieh PB, Smith EC, Kwon JM, Zaidman CM, Schultz M, Feltner DE, Tauscher-Wisniewski S, Ouyang H, Chand DH, Sproule DM, Macek TA, Mendell JR (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20:284\u2013293. https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6","journal-title":"Lancet Neurol"},{"key":"13314_CR41","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Wigderson M, Tauscher-Wisniewski S, McGill BE, Macek TA (2022) Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med 28:1390\u20131397. https:\/\/doi.org\/10.1038\/s41591-022-01867-3","journal-title":"Nat Med"},{"key":"13314_CR42","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Tauscher-Wisniewski S, McGill BE, Macek TA (2022) Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med 28:1381\u20131389. https:\/\/doi.org\/10.1038\/s41591-022-01866-4","journal-title":"Nat Med"},{"key":"13314_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JND-230197","volume":"11","author":"B Sitas","year":"2024","unstructured":"Sitas B, Hancevic M, Bilic K, Bilic H, Bilic E (2024) Risdiplam real world data - looking beyond motor neurons and motor function measures. J Neuromuscul Dis 11:75\u201384. https:\/\/doi.org\/10.3233\/JND-230197","journal-title":"J Neuromuscul Dis"},{"key":"13314_CR44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41434-022-00341-6","volume":"30","author":"I Bitetti","year":"2023","unstructured":"Bitetti I, Lanzara V, Margiotta G, Varone A (2023) Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. Gene Ther 30:592\u2013597. https:\/\/doi.org\/10.1038\/s41434-022-00341-6","journal-title":"Gene Ther"},{"key":"13314_CR45","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.eclinm.2023.101997","volume":"59","author":"M Pane","year":"2023","unstructured":"Pane M, Berti B, Capasso A, Coratti G, Varone A, D\u2019Amico A, Messina S, Masson R, Sansone VA, Donati MA, Agosto C, Bruno C, Ricci F, Pini A, Gagliardi D, Filosto M, Corti S, Leone D, Palermo C, Onesimo R, De Sanctis R, Ricci M, Bitetti I, Sframeli M, Dosi C, Albamonte E, Ticci C, Brolatti N, Bertini E, Finkel R, Mercuri E, ITASMAc Group (2023) Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies. EClinicalMedicine 59:101997. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101997","journal-title":"EClinicalMedicine"},{"key":"13314_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03562-x","volume":"24","author":"B Bjelica","year":"2024","unstructured":"Bjelica B, Wohnrade C, Cespedes I, Osmanovic A, Schreiber-Katz O, Petri S (2024) Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction. BMC Neurol 24:67. https:\/\/doi.org\/10.1186\/s12883-024-03562-x","journal-title":"BMC Neurol"},{"key":"13314_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03260-1","author":"T Hagenacker","year":"2025","unstructured":"Hagenacker T, Paradis AD, Lawson-Michod KA, Youn B (2025) Systematic review and meta-analysis of long-term nusinersen effectiveness in adolescents and adults with spinal muscular atrophy. Adv Ther. https:\/\/doi.org\/10.1007\/s12325-025-03260-1","journal-title":"Adv Ther"},{"key":"13314_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti G, Cutrona C, Pera MC, Bovis F, Ponzano M, Chieppa F, Antonaci L, Sansone V, Finkel R, Pane M, Mercuri E (2021) Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis 16:430. https:\/\/doi.org\/10.1186\/s13023-021-02065-z","journal-title":"Orphanet J Rare Dis"},{"key":"13314_CR49","doi-asserted-by":"publisher","first-page":"e200298","DOI":"10.1212\/CPJ.0000000000200298","volume":"14","author":"F Trucco","year":"2024","unstructured":"Trucco F, Ridout D, Weststrate H, Scoto M, Rohwer A, Coratti G, Main ML, Mayhew AG, Montes J, De Sanctis R, Pane M, Pera MC, Sansone VA, Albamonte E, D\u2019Amico A, Bruno C, Messina SS, Childs AM, Willis T, Ong MT, Servais L, Majumdar A, Hughes I, Marini-Bettolo C, Parasuraman D, Gowda VL, Baranello G, Bertini ES, De Vivo DC, Darras BT, Day JW, Mayer O, Zolkipli-Cunningham Z, Finkel RS, Mercuri E, Muntoni F, For iSMAc (2024) Therapeutic role of nusinersen on respiratory progression in pediatric patients with spinal muscular atrophy type 2 and nonambulant type 3. Neurol Clin Pract 14:e200298. https:\/\/doi.org\/10.1212\/CPJ.0000000000200298","journal-title":"Neurol Clin Pract"},{"key":"13314_CR50","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.sleep.2025.02.034","volume":"129","author":"A Chacko","year":"2025","unstructured":"Chacko A, Sly PD, Ware RS, Dyer B, Deegan S, Thomas N, Gauld LM (2025) Differential respiratory function response in paediatric spinal muscular atrophy types 2 and 3 treated with nusinersen over 3 years. Sleep Med 129:354\u2013362. https:\/\/doi.org\/10.1016\/j.sleep.2025.02.034","journal-title":"Sleep Med"},{"key":"13314_CR51","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1002\/mus.26457","volume":"59","author":"F Salmin","year":"2019","unstructured":"Salmin F, Albamonte E, Morettini V, Gagliano N, Mercuri E, Sansone VA (2019) Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy. Muscle Nerve 59:E42\u2013E44. https:\/\/doi.org\/10.1002\/mus.26457","journal-title":"Muscle Nerve"},{"key":"13314_CR52","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.4103\/NRR.NRR-D-24-00067","volume":"20","author":"X Xing","year":"2025","unstructured":"Xing X, Liu X, Li X, Li M, Wu X, Huang X, Xu A, Liu Y, Zhang J (2025) Insights into spinal muscular atrophy from molecular biomarkers. Neural Regen Res 20:1849\u20131863. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-00067","journal-title":"Neural Regen Res"},{"key":"13314_CR53","doi-asserted-by":"publisher","first-page":"117727192110356","DOI":"10.1177\/11772719211035643","volume":"16","author":"MG Pino","year":"2021","unstructured":"Pino MG, Rich KA, Kolb SJ (2021) Update on biomarkers in spinal muscular atrophy. Biomark Insights 16:11772719211035644. https:\/\/doi.org\/10.1177\/11772719211035643","journal-title":"Biomark Insights"},{"key":"13314_CR54","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3233\/JND-230054","volume":"10","author":"J Glascock","year":"2023","unstructured":"Glascock J, Darras BT, Crawford TO, Sumner CJ, Kolb SJ, DiDonato C, Elsheikh B, Howell K, Farwell W, Valente M, Petrillo M, Tingey J, Jarecki J (2023) Identifying biomarkers of spinal muscular atrophy for further development. J Neuromuscul Dis 10:937\u2013954. https:\/\/doi.org\/10.3233\/JND-230054","journal-title":"J Neuromuscul Dis"},{"key":"13314_CR55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JND-190428","volume":"6","author":"K Vill","year":"2019","unstructured":"Vill K, K\u00f6lbel H, Schwartz O, Blaschek A, Olgem\u00f6ller B, Harms E, Burggraf S, R\u00f6schinger W, Durner J, Gl\u00e4ser D, Nennstiel U, Wirth B, Schara U, Jensen B, Becker M, Hohenfellner K, M\u00fcller-Felber W (2019) One year of newborn screening for SMA - results of a German pilot project. J Neuromuscul Dis 6:503\u2013515. https:\/\/doi.org\/10.3233\/JND-190428","journal-title":"J Neuromuscul Dis"},{"key":"13314_CR56","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41436-020-0754-0","volume":"22","author":"X Chen","year":"2020","unstructured":"Chen X, Sanchis-Juan A, French CE, Connell AJ, Delon I, Kingsbury Z, Chawla A, Halpern AL, Taft RJ, Bentley DR, Butchbach MER, Raymond FL, Eberle MA (2020) Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. Genet Med 22:945\u2013953. https:\/\/doi.org\/10.1038\/s41436-020-0754-0","journal-title":"Genet Med"},{"key":"13314_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/ijns11010007","volume":"11","author":"A Berzal-Serrano","year":"2025","unstructured":"Berzal-Serrano A, Garc\u00eda-Boh\u00f3rquez B, Aller E, Jaijo T, Pitarch-Castellano I, Rausell D, Garc\u00eda-Garc\u00eda G, Mill\u00e1n JM (2025) Outcomes of a pilot newborn screening program for spinal muscular atrophy in the valencian community. Int J Neonatal Screen 11:7. https:\/\/doi.org\/10.3390\/ijns11010007","journal-title":"Int J Neonatal Screen"},{"key":"13314_CR58","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","volume":"15","author":"T Dangouloff","year":"2019","unstructured":"Dangouloff T, Servais L (2019) Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag 15:1153\u20131161. https:\/\/doi.org\/10.2147\/TCRM.S172291","journal-title":"Ther Clin Risk Manag"},{"key":"13314_CR59","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","volume":"85","author":"TW Prior","year":"2009","unstructured":"Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, Burghes AHM, Kissel JT (2009) A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet 85:408\u2013413. https:\/\/doi.org\/10.1016\/j.ajhg.2009.08.002","journal-title":"Am J Hum Genet"},{"key":"13314_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","volume":"4","author":"MD Mailman","year":"2002","unstructured":"Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, Burghes AHM, Prior TW (2002) Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 4:20\u201326. https:\/\/doi.org\/10.1097\/00125817-200201000-00004","journal-title":"Genet Med"},{"key":"13314_CR61","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, March F, Vencesl\u00e1 A, Rodr\u00edguez-\u00c1lvarez FJ, Aller E, Fern\u00e1ndez RM, Borrego S, Mill\u00e1n JM, Hern\u00e1ndez-Chico C, Cusc\u00f3 I, Fuentes-Prior P, Tizzano EF (2018) Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28:208\u2013215. https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003","journal-title":"Neuromuscul Disord"},{"key":"13314_CR62","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/mus.21350","volume":"40","author":"B Elsheikh","year":"2009","unstructured":"Elsheikh B, Prior T, Zhang X, Miller R, Kolb SJ, Moore D, Bradley W, Barohn R, Bryan W, Gelinas D, Iannaccone S, Leshner R, Mendell JR, Mendoza M, Russman B, Smith S, King W, Kissel JT (2009) An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve 40:652\u2013656. https:\/\/doi.org\/10.1002\/mus.21350","journal-title":"Muscle Nerve"},{"key":"13314_CR63","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N (2020) Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet 21:231\u2013261. https:\/\/doi.org\/10.1146\/annurev-genom-102319-103602","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"13314_CR64","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","volume":"119","author":"B Wirth","year":"2006","unstructured":"Wirth B, Brichta L, Schrank B, Lochm\u00fcller H, Blick S, Baasner A, Heller R (2006) Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 119:422\u2013428. https:\/\/doi.org\/10.1007\/s00439-006-0156-7","journal-title":"Hum Genet"},{"key":"13314_CR65","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","volume":"88","author":"RI Wadman","year":"2017","unstructured":"Wadman RI, Stam M, Gijzen M, Lemmink HH, Snoeck IN, Wijngaarde CA, Braun KPJ, Schoenmakers MAGC, Van Den Berg LH, Dooijes D, Van Der Pol WL (2017) Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134. J Neurol Neurosurg Psychiatry 88:365\u2013367. https:\/\/doi.org\/10.1136\/jnnp-2016-314292","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13314_CR66","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.cca.2012.07.020","volume":"413","author":"WJ Chen","year":"2012","unstructured":"Chen WJ, He J, Zhang QJ, Lin QF, Chen YF, Lin XZ, Lin MT, Murong SX, Wang N (2012) Modification of phenotype by SMN2 copy numbers in two Chinese families with SMN1 deletion in two continuous generations. Clin Chim Acta 413:1855\u20131860. https:\/\/doi.org\/10.1016\/j.cca.2012.07.020","journal-title":"Clin Chim Acta"},{"key":"13314_CR67","doi-asserted-by":"publisher","first-page":"1308296","DOI":"10.3389\/fneur.2024.1308296","volume":"15","author":"C Dosi","year":"2024","unstructured":"Dosi C, Masson R (2024) The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review. Front Neurol 15:1308296. https:\/\/doi.org\/10.3389\/fneur.2024.1308296","journal-title":"Front Neurol"},{"key":"13314_CR68","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/ana.26788","volume":"94","author":"M Ricci","year":"2023","unstructured":"Ricci M, Cicala G, Capasso A, Coratti G, Fiori S, Cutrona C, D\u2019Amico A, Sansone VA, Bruno C, Messina S, Mongini T, Coccia M, Siciliano G, Pegoraro E, Masson R, Filosto M, Comi GP, Corti S, Ronchi D, Maggi L et al (2023) Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 copies: are they really all stable? Ann Neurol 94:1126\u20131135. https:\/\/doi.org\/10.1002\/ana.26788","journal-title":"Ann Neurol"},{"key":"13314_CR69","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00415-005-0912-y","volume":"253","author":"I Cusc\u00f3","year":"2006","unstructured":"Cusc\u00f3 I, Barcel\u00f3 MJ, Rojas-Garc\u00eda R, Illa I, G\u00e1mez J, Cervera C, Pou A, Izquierdo G, Baiget M, Tizzano EF (2006) SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings. J Neurol 253:21\u201325. https:\/\/doi.org\/10.1007\/s00415-005-0912-y","journal-title":"J Neurol"},{"key":"13314_CR70","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1389202919666180101154916","volume":"19","author":"MA Maretina","year":"2018","unstructured":"Maretina MA, Zheleznyakova GY, Lanko KM, Egorova AA, Baranov VS, Kiselev AV (2018) Molecular factors involved in spinal muscular atrophy pathways as possible disease-modifying candidates. Curr Genomics 19:339\u2013355. https:\/\/doi.org\/10.2174\/1389202919666180101154916","journal-title":"Curr Genomics"},{"key":"13314_CR71","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/humu.24200","volume":"42","author":"L Blasco-P\u00e9rez","year":"2021","unstructured":"Blasco-P\u00e9rez L, Paramonov I, Leno J, Bernal S, Alias L, Fuentes-Prior P, Cusc\u00f3 I, Tizzano EF (2021) Beyond copy number: a new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients. Hum Mutat 42:787\u2013795. https:\/\/doi.org\/10.1002\/humu.24200","journal-title":"Hum Mutat"},{"key":"13314_CR72","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","volume":"138","author":"C Ruhno","year":"2019","unstructured":"Ruhno C, McGovern VL, Avenarius MR, Snyder PJ, Prior TW, Nery FC, Muhtaseb A, Roggenbuck JS, Kissel JT, Sansone VA, Siranosian JJ, Johnstone AJ, Nwe PH, Zhang RZ, Swoboda KJ, Burghes AHM (2019) Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype. Hum Genet 138:241\u2013256. https:\/\/doi.org\/10.1007\/s00439-019-01983-0","journal-title":"Hum Genet"},{"key":"13314_CR73","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea GE, Kr\u00f6ber S, McWhorter ML, Rossoll W, M\u00fcller S, Krawczak M, Bassell GJ, Beattie CE, Wirth B (2008) Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320:524\u2013527. https:\/\/doi.org\/10.1126\/science.1155085","journal-title":"Science"},{"key":"13314_CR74","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.nmd.2011.03.009","volume":"21","author":"S Bernal","year":"2011","unstructured":"Bernal S, Also-Rallo E, Mart\u00ednez-Hern\u00e1ndez R, Al\u00edas L, Rodr\u00edguez-Alvarez FJ, Mill\u00e1n JM, Hern\u00e1ndez-Chico C, Baiget M, Tizzano EF (2011) Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings. Neuromuscul Disord 21:413\u2013419. https:\/\/doi.org\/10.1016\/j.nmd.2011.03.009","journal-title":"Neuromuscul Disord"},{"key":"13314_CR75","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","volume":"100","author":"M Riessland","year":"2017","unstructured":"Riessland M, Kaczmarek A, Schneider S, Swoboda KJ, L\u00f6hr H, Bradler C, Grysko V, Dimitriadi M, Hosseinibarkooie S, Torres-Benito L, Peters M, Upadhyay A, Biglari N, Kr\u00f6ber S, H\u00f6lker I, Garbes L, Gilissen C, Hoischen A, N\u00fcrnberg G, N\u00fcrnberg P, Walter M, Rigo F, Bennett CF, Kye MJ, Hart AC, Hammerschmidt M, Kloppenburg P, Wirth B (2017) Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet 100:297\u2013315. https:\/\/doi.org\/10.1016\/j.ajhg.2017.01.005","journal-title":"Am J Hum Genet"},{"key":"13314_CR76","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","volume":"57","author":"KJ Swoboda","year":"2005","unstructured":"Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB (2005) Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 57:704\u2013712. https:\/\/doi.org\/10.1002\/ana.20473","journal-title":"Ann Neurol"},{"key":"13314_CR77","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/mus.21838","volume":"42","author":"A Lewelt","year":"2010","unstructured":"Lewelt A, Krosschell KJ, Scott C, Sakonju A, Kissel JT, Crawford TO, Acsadi G, D\u2019Anjou G, Elsheikh B, Reyna SP, Schroth MK, Maczulski JA, Stoddard GJ, Elovic E, Swoboda KJ (2010) Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 42:703\u2013708. https:\/\/doi.org\/10.1002\/mus.21838","journal-title":"Muscle Nerve"},{"key":"13314_CR78","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT, NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators (2017) Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 82:883\u2013891. https:\/\/doi.org\/10.1002\/ana.25101","journal-title":"Ann Neurol"},{"key":"13314_CR79","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JND-180327","volume":"5","author":"KJ Krosschell","year":"2018","unstructured":"The NeuroNEXT Clinical Trial Network, NN101 SMA Biomarker Investigators, Krosschell KJ, Bosch M, Nelson L, Duong T, Lowes LP, Alfano LN, Benjamin D, Carry TB, Devine G, Kelley C, Gadekan R, Malkus EC, Pasternak A, Provance-Orr S, Roemeiser-Logan L, Nicorici A, Trussell D, Young SD, Fetterman JR et al (2018) Motor function test reliability during the NeuroNEXT spinal muscular atrophy infant biomarker study. J Neuromuscul Dis 5:509\u2013521. https:\/\/doi.org\/10.3233\/JND-180327","journal-title":"J Neuromuscul Dis"},{"key":"13314_CR80","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","volume":"22","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D, Russell JS, Wiley V, Alexander IE, Farrar MA (2020) The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med 22:557\u2013565. https:\/\/doi.org\/10.1038\/s41436-019-0673-0","journal-title":"Genet Med"},{"key":"13314_CR81","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","volume":"23","author":"WC Weng","year":"2021","unstructured":"Weng WC, Hsu YK, Chang FM, Lin CY, Hwu WL, Lee WT, Lee NC, Chien YH (2021) CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening. Genet Med 23:415\u2013420. https:\/\/doi.org\/10.1038\/s41436-020-00987-w","journal-title":"Genet Med"},{"key":"13314_CR82","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","volume":"233","author":"A Petzold","year":"2005","unstructured":"Petzold A (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233:183\u2013198. https:\/\/doi.org\/10.1016\/j.jns.2005.03.015","journal-title":"J Neurol Sci"},{"key":"13314_CR83","doi-asserted-by":"publisher","first-page":"a018309","DOI":"10.1101\/cshperspect.a018309","volume":"9","author":"A Yuan","year":"2017","unstructured":"Yuan A, Rao MV, Veeranna NRA (2017) Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 9:a018309. https:\/\/doi.org\/10.1101\/cshperspect.a018309","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"13314_CR84","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00441-014-2082-7","volume":"360","author":"BJ Gentil","year":"2015","unstructured":"Gentil BJ, Tibshirani M, Durham HD (2015) Neurofilament dynamics and involvement in neurological disorders. Cell Tissue Res 360:609\u2013620. https:\/\/doi.org\/10.1007\/s00441-014-2082-7","journal-title":"Cell Tissue Res"},{"key":"13314_CR85","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1007\/s00018-004-4268-8","volume":"61","author":"Q Liu","year":"2004","unstructured":"Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, Moreira PI, Zhua X, Smith MA, Perry G (2004) Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 61:3057\u20133075. https:\/\/doi.org\/10.1007\/s00018-004-4268-8","journal-title":"Cell Mol Life Sci"},{"key":"13314_CR86","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12035-008-8033-0","volume":"38","author":"R Perrot","year":"2008","unstructured":"Perrot R, Berges R, Bocquet A, Eyer J (2008) Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol 38:27\u201365. https:\/\/doi.org\/10.1007\/s12035-008-8033-0","journal-title":"Mol Neurobiol"},{"key":"13314_CR87","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","volume":"6","author":"BT Darras","year":"2019","unstructured":"Darras BT, Crawford TO, Finkel RS, Mercuri E, De Vivo DC, Oskoui M, Tizzano EF, Ryan MM, Muntoni F, Zhao G, Staropoli J, McCampbell A, Petrillo M, Stebbins C, Fradette S, Farwell W, Sumner CJ (2019) Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 6:932\u2013944. https:\/\/doi.org\/10.1002\/acn3.779","journal-title":"Ann Clin Transl Neurol"},{"key":"13314_CR88","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","volume":"23","author":"CRR Alves","year":"2021","unstructured":"Alves CRR, Petrillo M, Spellman R, Garner R, Zhang R, Kiefer M, Simeone S, Sohn J, Eichelberger EJ, Rodrigues E, Arruda EA, Townsend EL, Farwell W, Swoboda KJ (2021) Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series. Mol Ther Methods Clin Dev 23:524\u2013538. https:\/\/doi.org\/10.1016\/j.omtm.2021.10.011","journal-title":"Mol Ther Methods Clin Dev"},{"key":"13314_CR89","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, Kirschner J, Kuntz NL, Parsons JA, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Staropoli JF, Kerr D, Sandrock AW, Stebbins C et al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 29:842\u2013856. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007","journal-title":"Neuromuscul Disord"},{"key":"13314_CR90","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/acn3.51449","volume":"8","author":"E Nitz","year":"2021","unstructured":"Nitz E, Smitka M, Schallner J, Akg\u00fcn K, Ziemssen T, Von Der Hagen M, T\u00fcngler V (2021) Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann Clin Transl Neurol 8:2013\u20132024. https:\/\/doi.org\/10.1002\/acn3.51449","journal-title":"Ann Clin Transl Neurol"},{"key":"13314_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1269406","volume":"14","author":"M Flotats-Bastardas","year":"2023","unstructured":"Flotats-Bastardas M, Bitzan L, Grell C, Martakis K, Winter B, Zemlin M, Wurster CD, Uzelac Z, Wei\u00df C, Hahn A (2023) Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi. Front Neurol 14:1269406. https:\/\/doi.org\/10.3389\/fneur.2023.1269406","journal-title":"Front Neurol"},{"key":"13314_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12112486","author":"M Maretina","year":"2024","unstructured":"Maretina M, Koroleva V, Shchugareva L, Glotov A, Kiselev A (2024) The relevance of spinal muscular atrophy biomarkers in the treatment era. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12112486","journal-title":"Biomedicines"},{"key":"13314_CR93","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/mus.26909","volume":"62","author":"S Verma","year":"2020","unstructured":"Verma S, Forte J, Ritchey M, Shah D (2020) Motor unit number index in children with later-onset spinal muscular atrophy. Muscle Nerve 62:633\u2013637. https:\/\/doi.org\/10.1002\/mus.26909","journal-title":"Muscle Nerve"},{"key":"13314_CR94","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","volume":"92","author":"D Kariyawasam","year":"2021","unstructured":"Kariyawasam D, D\u2019Silva A, Howells J, Herbert K, Geelan-Small P, Lin CSY, Farrar MA (2021) Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry 92:78\u201385. https:\/\/doi.org\/10.1136\/jnnp-2020-324254","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13314_CR95","doi-asserted-by":"publisher","unstructured":"Axente M (2021) Clinical and electrophysiological aspects in children with spinal muscular atrophy type 1, 2 and 3 before treatment. JNND 9. Available at: https:\/\/www.jscholaronline.org\/full-text\/JNND\/9_103\/Clinical-and-Electrophysiological-Aspects.php [Accessed 5 Feb 2025]. https:\/\/doi.org\/10.17303\/jnnd.2021.9.103","DOI":"10.17303\/jnnd.2021.9.103"},{"key":"13314_CR96","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","volume":"79","author":"P Kaufmann","year":"2012","unstructured":"Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, Oskoui M, Constantinescu A, Gooch CL, Foley AR, Yang ML, Tawil R, Chung WK, Martens WB, Montes J, Battista V, O\u2019Hagen J, Dunaway S, Flickinger J, Quigley J et al (2012) Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 79:1889\u20131897. https:\/\/doi.org\/10.1212\/WNL.0b013e318271f7e4","journal-title":"Neurology"},{"key":"13314_CR97","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/mus.23967","volume":"49","author":"PB Kang","year":"2014","unstructured":"Kang PB, Gooch CL, McDermott MP, Darras BT, Finkel RS, Yang ML, Sproule DM, Chung WK, Kaufmann P, De Vivo DC, Muscle Study Group and Pediatric Neuromuscular Clinical Research Network for Spinal Muscular Atrophy (2014) The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve 49:636\u2013644. https:\/\/doi.org\/10.1002\/mus.23967","journal-title":"Muscle Nerve"},{"key":"13314_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2024.104316","volume":"47","author":"Y Peng","year":"2025","unstructured":"Peng Y, Feng L, Wu J, Zhou Q, Liu H, Chen J, Song X, Han W, Zhang F, Yuan P, Yao Z, Xie L, Li M, Jiang L, Hong S (2025) Motor function and compound muscle action potential amplitude in children with spinal muscular atrophy treated with nusinersen. Brain Dev 47:104316. https:\/\/doi.org\/10.1016\/j.braindev.2024.104316","journal-title":"Brain Dev"},{"key":"13314_CR99","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.arcped.2023.08.011","volume":"31","author":"M Richard","year":"2024","unstructured":"Richard M, Barrois R, Desguerre I, Deladri\u00e8re E, Leloup-Germa V, Barnerias C, Gitiaux C (2024) Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen. Arch Pediatr 31:26\u201331. https:\/\/doi.org\/10.1016\/j.arcped.2023.08.011","journal-title":"Arch Pediatr"},{"key":"13314_CR100","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.3390\/pharmaceutics14102074","volume":"14","author":"M Axente","year":"2022","unstructured":"Axente M, Mirea A, Sporea C, P\u0103dure L, Dr\u0103goi CM, Nicolae AC, Ion DA (2022) Clinical and electrophysiological changes in pediatric spinal muscular atrophy after 2 years of nusinersen treatment. Pharmaceutics 14:2074. https:\/\/doi.org\/10.3390\/pharmaceutics14102074","journal-title":"Pharmaceutics"},{"key":"13314_CR101","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.nmd.2023.02.004","volume":"33","author":"R Barrois","year":"2023","unstructured":"Barrois R, Barnerias C, Deladri\u00e8re E, Leloup-Germa V, Tervil B, Audic F, Boulay C, Cances C, Cintas P, Davion JB, Espil-Taris C, Manel V, Pereon Y, Piarroux J, Quijano Roy S, Vuillerot C, Walther-Louvier U, Desguerre I, Gitiaux C (2023) A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (onasemnogene abeparvovec) SMA therapy. Neuromuscul Disord 33:309\u2013314. https:\/\/doi.org\/10.1016\/j.nmd.2023.02.004","journal-title":"Neuromuscul Disord"},{"key":"13314_CR102","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2147\/DDDT.S449066","volume":"18","author":"D Li","year":"2024","unstructured":"Li D, Sun N, Xiang L, Liu J, Wang X, Yang L, Huang S (2024) Neurophysiological characteristics in type II and type III 5q spinal muscular atrophy patients: impact of nusinersen treatment. Drug Des Devel Ther 18:953\u2013965. https:\/\/doi.org\/10.2147\/DDDT.S449066","journal-title":"Drug Des Devel Ther"},{"key":"13314_CR103","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.clinph.2020.01.018","volume":"131","author":"BTHM Sleutjes","year":"2020","unstructured":"Sleutjes BTHM, Wijngaarde CA, Wadman RI, Otto LAM, Asselman FL, Cuppen I, Van Den Berg LH, Van Der Pol WL, Goedee HS (2020) Assessment of motor unit loss in patients with spinal muscular atrophy. Clin Neurophysiol 131:1280\u20131286. https:\/\/doi.org\/10.1016\/j.clinph.2020.01.018","journal-title":"Clin Neurophysiol"},{"key":"13314_CR104","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.nmd.2014.11.012","volume":"25","author":"M Gawel","year":"2015","unstructured":"Gawel M, Kostera-Pruszczyk A, Lusakowska A, Jedrzejowska M, Ryniewicz B, Lipowska M, Gawel D, Kaminska A (2015) Motor unit loss estimation by the multipoint incremental MUNE method in children with spinal muscular atrophy - a preliminary study. Neuromuscul Disord 25:216\u2013221. https:\/\/doi.org\/10.1016\/j.nmd.2014.11.012","journal-title":"Neuromuscul Disord"},{"key":"13314_CR105","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1007\/s00415-023-11787-y","volume":"270","author":"HS Lapp","year":"2023","unstructured":"Lapp HS, Freigang M, Hagenacker T, Weiler M, Wurster CD, G\u00fcnther R (2023) Biomarkers in 5q-associated spinal muscular atrophy-a narrative review. J Neurol 270:4157\u20134178. https:\/\/doi.org\/10.1007\/s00415-023-11787-y","journal-title":"J Neurol"},{"key":"13314_CR106","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, Rostasy K, Blennow K, Zetterberg H, Tulinius M (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266:2129\u20132136. https:\/\/doi.org\/10.1007\/s00415-019-09389-8","journal-title":"J Neurol"},{"key":"13314_CR107","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.braindev.2023.07.005","volume":"45","author":"G Seo","year":"2023","unstructured":"Seo G, Kim S, Byun JC, Kwon S, Lee YJ (2023) Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen. Brain Dev 45:554\u2013563. https:\/\/doi.org\/10.1016\/j.braindev.2023.07.005","journal-title":"Brain Dev"},{"key":"13314_CR108","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1515\/cclm-2023-1311","volume":"62","author":"S Bayoumy","year":"2024","unstructured":"Bayoumy S, Verberk IMW, Vermunt L, Willemse E, Den Dulk B, Van Der Ploeg AT, Pajkrt D, Nitz E, Van Den Hout JMP, Van Der Post J, Wolf NI, Beerepoot S, Groen EJN, T\u00fcngler V, Teunissen CE (2024) Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clin Chem Lab Med 62:1252\u20131265. https:\/\/doi.org\/10.1515\/cclm-2023-1311","journal-title":"Clin Chem Lab Med"},{"key":"13314_CR109","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.braindev.2019.12.006","volume":"42","author":"T Tozawa","year":"2020","unstructured":"Tozawa T, Kasai T, Tatebe H, Shiomi K, Nishio H, Tokuda T, Chiyonobu T (2020) Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: a case report focusing on the neurofilament light chain in cerebrospinal fluid. Brain Dev 42:311\u2013314. https:\/\/doi.org\/10.1016\/j.braindev.2019.12.006","journal-title":"Brain Dev"},{"key":"13314_CR110","unstructured":"European Medicines Agency (2022). Letter of support of neurofilament light in childhood neurological diseases. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/other\/letter-support-neurofilament-lightchildhood-neurological-diseases_en.pdf"},{"key":"13314_CR111","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1177\/0883073811405053","volume":"26","author":"DM Sproule","year":"2011","unstructured":"Sproule DM, Montgomery MJ, Punyanitya M, Shen W, Dashnaw S, Montes J, Dunaway S, Finkel R, Darras B, De Vivo DC, Kaufmann P (2011) Thigh muscle volume measured by magnetic resonance imaging is stable over a 6-month interval in spinal muscular atrophy. J Child Neurol 26:1252\u20131259. https:\/\/doi.org\/10.1177\/0883073811405053","journal-title":"J Child Neurol"},{"key":"13314_CR112","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/0883073810380457","volume":"26","author":"DM Sproule","year":"2011","unstructured":"Sproule DM, Punyanitya M, Shen W, Dashnaw S, Martens B, Montgomery M, Montes J, Battista V, Finkel R, Darras B, De Vivo DC, Kaufmann P (2011) Muscle volume estimation by magnetic resonance imaging in spinal muscular atrophy. J Child Neurol 26:309\u2013317. https:\/\/doi.org\/10.1177\/0883073810380457","journal-title":"J Child Neurol"},{"key":"13314_CR113","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00415-019-09646-w","volume":"267","author":"C Brogna","year":"2020","unstructured":"Brogna C, Cristiano L, Verdolotti T, Pichiecchio A, Cinnante C, Sansone V, Sconfienza LM, Berardinelli A, Garibaldi M, Antonini G, Pane M, Pera MC, Antonaci L, Ficociello L, Albamonte E, Tasca G, Begliuomini C, Tartaglione T, Maggi L, Govoni A et al (2020) MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients. J Neurol 267:898\u2013912. https:\/\/doi.org\/10.1007\/s00415-019-09646-w","journal-title":"J Neurol"},{"key":"13314_CR114","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1212\/WNL.0b013e3181eccf8f","volume":"75","author":"JS Wu","year":"2010","unstructured":"Wu JS, Darras BT, Rutkove SB (2010) Assessing spinal muscular atrophy with quantitative ultrasound. Neurology 75:526\u2013531. https:\/\/doi.org\/10.1212\/WNL.0b013e3181eccf8f","journal-title":"Neurology"},{"key":"13314_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201004","volume":"13","author":"A Chabanon","year":"2018","unstructured":"Chabanon A, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, De Waele L, Cuisset JM, Laugel V, Schara U, Gidaro T, Gilabert S, Hogrel JY, Baudin PY, Carlier P, Fournier E, Lowes LP, Hellbach N, Seabrook T, Toledano E et al (2018) Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data nathis-SMA study. PLoS ONE 13:e0201004. https:\/\/doi.org\/10.1371\/journal.pone.0201004","journal-title":"PLoS ONE"},{"key":"13314_CR116","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jns.2015.08.1532","volume":"358","author":"KW Ng","year":"2015","unstructured":"Ng KW, Connolly AM, Zaidman CM (2015) Quantitative muscle ultrasound measures rapid declines over time in children with SMA type 1. J Neurol Sci 358:178\u2013182. https:\/\/doi.org\/10.1016\/j.jns.2015.08.1532","journal-title":"J Neurol Sci"},{"key":"13314_CR117","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JND-221671","volume":"11","author":"LAM Otto","year":"2024","unstructured":"Otto LAM, Froeling M, Van Eijk RPA, Wadman RI, Cuppen I, Van Der Woude DR, Bartels B, Asselman FL, Hendrikse J, Van Der Pol WL (2024) Monitoring nusinersen treatment effects in children with spinal muscular atrophy with quantitative muscle MRI. J Neuromuscul Dis 11:91\u2013101. https:\/\/doi.org\/10.3233\/JND-221671","journal-title":"J Neuromuscul Dis"},{"key":"13314_CR118","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40273-021-01118-2","volume":"40","author":"SH Lo","year":"2022","unstructured":"Lo SH, Lawrence C, Mart\u00ed Y, Caf\u00e9 A, Lloyd AJ (2022) Patient and caregiver treatment preferences in type 2 and non-ambulatory type 3 spinal muscular atrophy: a discrete choice experiment survey in five European countries. Pharmacoeconomics 40:103\u2013115. https:\/\/doi.org\/10.1007\/s40273-021-01118-2","journal-title":"Pharmacoeconomics"},{"key":"13314_CR119","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monnette","year":"2021","unstructured":"Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, Shi L (2021) Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis 16:36. https:\/\/doi.org\/10.1186\/s13023-020-01667-3","journal-title":"Orphanet J Rare Dis"},{"key":"13314_CR120","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, Aloysius A, Morrison L, Main M, Crawford TO, Trela A, Participants of the International Conference on SMA Standard of Care (2007) Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22:1027\u201349. https:\/\/doi.org\/10.1177\/0883073807305788","journal-title":"J Child Neurol"},{"key":"13314_CR121","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00586-022-07182-2","volume":"31","author":"M Angeli","year":"2022","unstructured":"Angeli M, Alpantaki K, Pandis N, Koutserimpas C, Hadjipavlou A (2022) The effect of scoliosis surgery on pulmonary function in spinal muscular atrophy patients: review of the literature and a meta-analysis. Eur Spine J 31:2279\u20132286. https:\/\/doi.org\/10.1007\/s00586-022-07182-2","journal-title":"Eur Spine J"},{"key":"13314_CR122","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s43390-020-00107-3","volume":"8","author":"MW Konigsberg","year":"2020","unstructured":"Konigsberg MW, Matsumoto H, Ball JR, Roye BD, Vitale MG (2020) Skip constructs in spinal muscular atrophy: outcomes of a novel approach for posterior spinal instrumentation and fusion. Spine Deform 8:1093\u20131097. https:\/\/doi.org\/10.1007\/s43390-020-00107-3","journal-title":"Spine Deform"},{"key":"13314_CR123","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/BF00301412","volume":"2","author":"C Granata","year":"1993","unstructured":"Granata C, Merlini L, Bonfiglioli S, Marini ML, Cervellati S (1993) Spine surgery in spinal muscular atrophy: long-term results. Eur Spine J 2:190\u2013197. https:\/\/doi.org\/10.1007\/BF00301412","journal-title":"Eur Spine J"},{"key":"13314_CR124","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205560","author":"H Moss","year":"2024","unstructured":"Moss H, Pfeifer C, Sands K, Peavey J, Chin I, Jin P, Mbagwu M (2024) Comparison of adult vs. pediatric patients with spinal muscular atrophy: an axon registry study (P2\u201311.006). Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000205560","journal-title":"Neurology"},{"key":"13314_CR125","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1111\/ene.15005","volume":"28","author":"C Schneider","year":"2021","unstructured":"Schneider C, Wassermann MK, Grether NB, Fink GR, Wunderlich G, Lehmann HC (2021) Motor unit number estimation in adult patients with spinal muscular atrophy treated with nusinersen. Eur J Neurol 28:3022\u20133029. https:\/\/doi.org\/10.1111\/ene.15005","journal-title":"Eur J Neurol"},{"key":"13314_CR126","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/mus.28091","volume":"70","author":"V Vacchiano","year":"2024","unstructured":"Vacchiano V, Morabito F, Faini C, Nocera G, Not R, Scarpini G, Romagnoli M, Pini A, Liguori R (2024) Motor unit number estimation via MSCANFIT MUNE in spinal muscular atrophy. Muscle Nerve 70:71\u201381. https:\/\/doi.org\/10.1002\/mus.28091","journal-title":"Muscle Nerve"},{"key":"13314_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13226881","volume":"13","author":"V Vacchiano","year":"2024","unstructured":"Vacchiano V, Morabito F, Bonan L, Teodorani L, Faini C, Rizzo G, Liguori R (2024) Reverse split hand as a neurophysiological hallmark of spinal muscular atrophy. J Clin Med 13:6881. https:\/\/doi.org\/10.3390\/jcm13226881","journal-title":"J Clin Med"},{"key":"13314_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.650532","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh B, Severyn S, Zhao S, Kline D, Linsenmayer M, Kelly K, Tellez M, Bartlett A, Heintzman S, Reynolds J, Sterling G, Weaver T, Rajneesh K, Kolb SJ, Arnold WD (2021) Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy. Front Neurol 12:650532. https:\/\/doi.org\/10.3389\/fneur.2021.650532","journal-title":"Front Neurol"},{"key":"13314_CR129","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.650535","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh B, Severyn S, Zhao S, Kline D, Linsenmayer M, Kelly K, Tellez M, Bartlett A, Heintzman S, Reynolds J, Sterling G, Weaver T, Rajneesh K, Kolb SJ, Arnold WD (2021) Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA. Front Neurol 12:650535. https:\/\/doi.org\/10.3389\/fneur.2021.650535","journal-title":"Front Neurol"},{"key":"13314_CR130","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16099","volume":"31","author":"T Kessler","year":"2024","unstructured":"Kessler T, Sam G, Wick W, Weiler M (2024) Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: a systematic comparison of electrophysiologic with clinical outcome measures. Eur J Neurol 31:e16099. https:\/\/doi.org\/10.1111\/ene.16099","journal-title":"Eur J Neurol"},{"key":"13314_CR131","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clinph.2018.11.009","volume":"130","author":"R G\u00fcnther","year":"2019","unstructured":"G\u00fcnther R, Neuwirth C, Koch JC, Lingor P, Braun N, Untucht R, Petzold D, Weber M, Hermann A (2019) Motor unit number index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy. Clin Neurophysiol 130:315\u2013319. https:\/\/doi.org\/10.1016\/j.clinph.2018.11.009","journal-title":"Clin Neurophysiol"},{"key":"13314_CR132","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.clinph.2018.08.025","volume":"129","author":"G Querin","year":"2018","unstructured":"Querin G, Lenglet T, Debs R, Stojkovic T, Behin A, Salachas F, Le Forestier N, Amador MDM, Lacomblez L, Meininger V, Bruneteau G, Lafor\u00eat P, Blancho S, Marchand-Pauvert V, Bede P, Hogrel JY, Pradat PF (2018) The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy. Clin Neurophysiol 129:2333\u20132340. https:\/\/doi.org\/10.1016\/j.clinph.2018.08.025","journal-title":"Clin Neurophysiol"},{"key":"13314_CR133","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/mus.27809","volume":"67","author":"A Barp","year":"2023","unstructured":"Barp A, Carraro E, Salmin F, Lizio A, Cheli M, Sansone V (2023) Facial nerve vulnerability in spinal muscular atrophy and motor unit number index of the orbicularis oculi muscle. Muscle Nerve 67:401\u2013406. https:\/\/doi.org\/10.1002\/mus.27809","journal-title":"Muscle Nerve"},{"key":"13314_CR134","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4357","volume":"33","author":"LAM Otto","year":"2020","unstructured":"Otto LAM, Van Der Pol W, Schlaffke L, Wijngaarde CA, Stam M, Wadman RI, Cuppen I, Van Eijk RPA, Asselman F, Bartels B, Van Der Woude D, Hendrikse J, Froeling M (2020) Quantitative MRI of skeletal muscle in a cross-sectional cohort of patients with spinal muscular atrophy types 2 and 3. NMR Biomed 33:e4357. https:\/\/doi.org\/10.1002\/nbm.4357","journal-title":"NMR Biomed"},{"key":"13314_CR135","doi-asserted-by":"publisher","first-page":"e4473","DOI":"10.1002\/nbm.4473","volume":"34","author":"LAM Otto","year":"2021","unstructured":"Otto LAM, Froeling M, Van Eijk RPA, Asselman F, Wadman R, Cuppen I, Hendrikse J, Van Der Pol W (2021) Quantification of disease progression in spinal muscular atrophy with muscle MRI-a pilot study. NMR Biomed 34:e4473. https:\/\/doi.org\/10.1002\/nbm.4473","journal-title":"NMR Biomed"},{"key":"13314_CR136","doi-asserted-by":"publisher","first-page":"e4696","DOI":"10.1002\/nbm.4696","volume":"35","author":"MT Hooijmans","year":"2022","unstructured":"Hooijmans MT, Habets LE, Van Den Berg-Faay SAM, Froeling M, Asselman F, Strijkers GJ, Jeneson JAL, Bartels B, Nederveen AJ, Van Der Pol WL (2022) Multi-parametric quantitative magnetic resonance imaging of the upper arm muscles of patients with spinal muscular atrophy. NMR Biomed 35:e4696. https:\/\/doi.org\/10.1002\/nbm.4696","journal-title":"NMR Biomed"},{"key":"13314_CR137","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.25385","volume":"55","author":"H Durmus","year":"2017","unstructured":"Durmus H, Yilmaz R, Gulsen-Parman Y, Oflazer-Serdaroglu P, Cuttini M, Dursun M, Deymeer F (2017) Muscle magnetic resonance imaging in spinal muscular atrophy type 3: selective and progressive involvement. Muscle Nerve 55:651\u2013656. https:\/\/doi.org\/10.1002\/mus.25385","journal-title":"Muscle Nerve"},{"key":"13314_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117067","volume":"417","author":"A Barp","year":"2020","unstructured":"Barp A, Carraro E, Albamonte E, Salmin F, Lunetta C, Comi GP, Messina C, Albano D, Chianca V, Sconfienza LM, Mercuri EM, Sansone VA (2020) Muscle MRI in two SMA patients on nusinersen treatment: a two years follow-up. J Neurol Sci 417:117067. https:\/\/doi.org\/10.1016\/j.jns.2020.117067","journal-title":"J Neurol Sci"},{"key":"13314_CR139","doi-asserted-by":"publisher","first-page":"76","DOI":"10.36185\/2532-1900-074","volume":"41","author":"A Gallone","year":"2022","unstructured":"Gallone A, Mazzi F, Bonanno S, Zanin R, Moscatelli M, Aquino D, Maggi L (2022) Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study. Acta Myol 41:76\u201383. https:\/\/doi.org\/10.36185\/2532-1900-074","journal-title":"Acta Myol"},{"key":"13314_CR140","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mus.28034","volume":"69","author":"L Pelosi","year":"2024","unstructured":"Pelosi L, Rodrigues M, Zhong C, Patel S, Roxburgh R (2024) Quantitative muscle ultrasound in adult spinal muscular atrophy: a pilot study. Muscle Nerve 69:349\u2013353. https:\/\/doi.org\/10.1002\/mus.28034","journal-title":"Muscle Nerve"},{"key":"13314_CR141","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3233\/JND-210735","volume":"9","author":"KA Rich","year":"2022","unstructured":"Rich KA, Fox A, Yalvac M, Heintzman S, Tellez M, Bartlett A, Severyn S, Linsenmayer M, Kelly K, Reynolds J, Sterling GB, Weaver T, Rajneesh K, Pino MG, Arnold WD, Elsheikh B, Kolb SJ (2022) Neurofilament levels in CSF and serum in an adult SMA cohort treated with nusinersen. J Neuromuscul Dis 9:111\u2013119. https:\/\/doi.org\/10.3233\/JND-210735","journal-title":"J Neuromuscul Dis"},{"key":"13314_CR142","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419846058","volume":"12","author":"CD Wurster","year":"2019","unstructured":"Wurster CD, G\u00fcnther R, Steinacker P, Dreyhaupt J, Wollinsky K, Uzelac Z, Witzel S, Kocak T, Winter B, Koch JC, Lingor P, Petri S, Ludolph AC, Hermann A, Otto M (2019) Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther Adv Neurol Disord 12:1756286419846058. https:\/\/doi.org\/10.1177\/1756286419846058","journal-title":"Ther Adv Neurol Disord"},{"key":"13314_CR143","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00415-019-09547-y","volume":"267","author":"CD Wurster","year":"2020","unstructured":"The MND-Net, Wurster CD, Steinacker P, G\u00fcnther R, Koch JC, Lingor P, Uzelac Z, Witzel S, Wollinsky K, Winter B, Osmanovic A, Schreiber-Katz O, Al Shweiki R, Ludolph AC, Petri S, Hermann A, Otto M (2020) Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. J Neurol 267:36\u201344. https:\/\/doi.org\/10.1007\/s00415-019-09547-y","journal-title":"J Neurol"},{"key":"13314_CR144","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1111\/jcmm.14939","volume":"24","author":"I Faravelli","year":"2020","unstructured":"Faravelli I, Meneri M, Saccomanno D, Velardo D, Abati E, Gagliardi D, Parente V, Petrozzi L, Ronchi D, Stocchetti N, Calderini E, D\u2019Angelo G, Chidini G, Prandi E, Ricci G, Siciliano G, Bresolin N, Comi GP, Corti S, Magri F et al (2020) Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on spinal muscular atrophy type 3 patients. J Cell Mol Med 24:3034\u20133039. https:\/\/doi.org\/10.1111\/jcmm.14939","journal-title":"J Cell Mol Med"},{"key":"13314_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215397","volume":"20","author":"A Totzeck","year":"2019","unstructured":"Totzeck A, Stolte B, Kizina K, Bolz S, Schlag M, Thimm A, Kleinschnitz C, Hagenacker T (2019) Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen. Int J Mol Sci 20:5397. https:\/\/doi.org\/10.3390\/ijms20215397","journal-title":"Int J Mol Sci"},{"key":"13314_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073810","volume":"25","author":"P Andr\u00e9s-Benito","year":"2024","unstructured":"Andr\u00e9s-Benito P, V\u00e1zquez-Costa JF, \u00d1ungo Garz\u00f3n NC, Colomina MJ, Marco C, Gonz\u00e1lez L, Terrafeta C, Dom\u00ednguez R, Ferrer I, Povedano M (2024) Neurodegeneration biomarkers in adult spinal muscular atrophy (SMA) patients treated with nusinersen. Int J Mol Sci 25:3810. https:\/\/doi.org\/10.3390\/ijms25073810","journal-title":"Int J Mol Sci"},{"key":"13314_CR147","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40261-021-01071-0","volume":"41","author":"G Milella","year":"2021","unstructured":"Milella G, Introna A, D\u2019Errico E, Fraddosio A, Scaglione G, Morea A, Ucci M, Ruggieri M, Mastrapasqua M, Megna M, Puntillo F, Simone IL (2021) Cerebrospinal fluid and clinical profiles in adult type 2\u20133 spinal muscular atrophy patients treated with nusinersen: an 18-month single-centre experience. Clin Drug Investig 41:775\u2013784. https:\/\/doi.org\/10.1007\/s40261-021-01071-0","journal-title":"Clin Drug Investig"},{"key":"13314_CR148","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213371","volume":"104","author":"I Cordts","year":"2025","unstructured":"Cordts I, Fuetterer C, Wachinger A, Von Heynitz R, Kessler T, Freigang M, Quinten AL, Bjelica B, Brakemeier S, Hobbiebrunken E, Hagenacker T, Petri S, Koch JC, Hahn A, Lingor P, Deschauer M, G\u00fcnther R, Weiler M, Haller B, Feneberg E (2025) Long-term dynamics of CSF and serum neurofilament light chain in adult patients with 5q spinal muscular atrophy treated with nusinersen. Neurology 104:e213371. https:\/\/doi.org\/10.1212\/WNL.0000000000213371","journal-title":"Neurology"},{"key":"13314_CR149","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1212\/01.wnl.0000201929.56928.13","volume":"66","author":"CJ Sumner","year":"2006","unstructured":"Sumner CJ, Kolb SJ, Harmison GG, Jeffries NO, Schadt K, Finkel RS, Dreyfuss G, Fischbeck KH (2006) SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 66:1067\u20131073. https:\/\/doi.org\/10.1212\/01.wnl.0000201929.56928.13","journal-title":"Neurology"},{"key":"13314_CR150","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/ana.20836","volume":"59","author":"L Brichta","year":"2006","unstructured":"Brichta L, Holker I, Haug K, Klockgether T, Wirth B (2006) In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 59:970\u2013975. https:\/\/doi.org\/10.1002\/ana.20836","journal-title":"Ann Neurol"},{"key":"13314_CR151","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1212\/01.wnl.0000252934.70676.ab","volume":"68","author":"LR Simard","year":"2007","unstructured":"Simard LR, B\u00e9langer MC, Morissette S, Wride M, Prior TW, Swoboda KJ (2007) Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology 68:451\u2013456. https:\/\/doi.org\/10.1212\/01.wnl.0000252934.70676.ab","journal-title":"Neurology"},{"key":"13314_CR152","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139950","volume":"10","author":"C Czech","year":"2015","unstructured":"Czech C, Tang W, Bugawan T, Mano C, Horn C, Iglesias VA, Fr\u00f6hner S, Zaworski PG, Paushkin S, Chen K, Kremer T (2015) Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls. PLoS ONE 10:e0139950. https:\/\/doi.org\/10.1371\/journal.pone.0139950","journal-title":"PLoS ONE"},{"key":"13314_CR153","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150640","volume":"11","author":"P Zaworski","year":"2016","unstructured":"Zaworski P, von Herrmann KM, Taylor S, Sunshine SS, McCarthy K, Risher N, Newcomb T, Weetall M, Prior TW, Swoboda KJ, Chen KS, Paushkin S (2016) SMN protein can be reliably measured in whole blood with an electrochemiluminescence (ECL) immunoassay: implications for clinical trials. PLoS ONE 11:e0150640. https:\/\/doi.org\/10.1371\/journal.pone.0150640","journal-title":"PLoS ONE"},{"key":"13314_CR154","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/mus.26995","volume":"62","author":"CRR Alves","year":"2020","unstructured":"Alves CRR, Zhang R, Johnstone AJ, Garner R, Eichelberger EJ, Lepez SDSD, Yi V, Stevens V, Poxson R, Schwartz R, Zaworski P, Swoboda KJ (2020) Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy. Muscle Nerve 62:351\u2013357. https:\/\/doi.org\/10.1002\/mus.26995","journal-title":"Muscle Nerve"},{"key":"13314_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2024.108462","volume":"244","author":"X Cheng","year":"2024","unstructured":"Cheng X, Li YN, Fan YB, Zhao HH, Li L, Lu C, Zhu LH, Niu Q (2024) Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients. Clin Neurol Neurosurg 244:108462. https:\/\/doi.org\/10.1016\/j.clineuro.2024.108462","journal-title":"Clin Neurol Neurosurg"},{"key":"13314_CR156","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/neurolint17030041","volume":"17","author":"A Belan\u010di\u0107","year":"2025","unstructured":"Belan\u010di\u0107 A, Jankovi\u0107 T, Gkrinia EMM, Kristi\u0107 I, Raji\u010d Bumber J, Ra\u010dki V, Pilipovi\u0107 K, Vitezi\u0107 D, Mr\u0161i\u0107-Pel\u010di\u0107 J (2025) Glial cells in spinal muscular atrophy: speculations on non-cell-autonomous mechanisms and therapeutic implications. Neurol Int 17:41. https:\/\/doi.org\/10.3390\/neurolint17030041","journal-title":"Neurol Int"},{"key":"13314_CR157","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omtn.2023.03.005","volume":"32","author":"TH Chen","year":"2023","unstructured":"Chen TH, Chang SH, Wu YF, Yen YP, Hsu FY, Chen YC, Ming Y, Hsu HC, Su YC, Wong ST, Hung JH, Chiou SH, Jong YJ, Chen JA (2023) MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice. Mol Ther Nucleic Acids 32:144\u2013160. https:\/\/doi.org\/10.1016\/j.omtn.2023.03.005","journal-title":"Mol Ther Nucleic Acids"},{"key":"13314_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.47","volume":"5","author":"F Catapano","year":"2016","unstructured":"Catapano F, Zaharieva I, Scoto M, Marrosu E, Morgan J, Muntoni F, Zhou H (2016) Altered levels of microRNA-9, -206, and -132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy. Mol Ther Nucleic Acids 5:e331. https:\/\/doi.org\/10.1038\/mtna.2016.47","journal-title":"Mol Ther Nucleic Acids"},{"key":"13314_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115673","volume":"22","author":"C Malacarne","year":"2021","unstructured":"Malacarne C, Galbiati M, Giagnorio E, Cavalcante P, Salerno F, Andreetta F, Cagnoli C, Taiana M, Nizzardo M, Corti S, Pensato V, Venerando A, Gellera C, Fenu S, Pareyson D, Masson R, Maggi L, Dalla Bella E, Lauria G, Mantegazza R et al (2021) Dysregulation of muscle-specific microRNAs as common pathogenic feature associated with muscle atrophy in ALS, SMA and SBMA: evidence from animal models and human patients. Int J Mol Sci 22:5673. https:\/\/doi.org\/10.3390\/ijms22115673","journal-title":"Int J Mol Sci"},{"key":"13314_CR160","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/hmg\/ddab365","volume":"31","author":"E Welby","year":"2022","unstructured":"Welby E, Rehborg RJ, Harmelink M, Ebert AD (2022) Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples. Hum Mol Genet 31:1830\u20131843. https:\/\/doi.org\/10.1093\/hmg\/ddab365","journal-title":"Hum Mol Genet"},{"key":"13314_CR161","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1111\/ene.15382","volume":"29","author":"I Magen","year":"2022","unstructured":"Magen I, Aharoni S, Yacovzada NS, Tokatly Latzer I, Alves CRR, Sagi L, Fattal-Valevski A, Swoboda KJ, Katz J, Bruckheimer E, Nevo Y, Hornstein E (2022) Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients. Eur J Neurol 29:2420\u20132430. https:\/\/doi.org\/10.1111\/ene.15382","journal-title":"Eur J Neurol"},{"key":"13314_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155060","volume":"12","author":"M Babi\u0107","year":"2023","unstructured":"Babi\u0107 M, Banovi\u0107 M, Bere\u010di\u0107 I, Bani\u0107 T, Babi\u0107 Leko M, Ulamec M, Junakovi\u0107 A, Kopi\u0107 J, Serti\u0107 J, Bari\u0161i\u0107 N, \u0160imi\u0107 G (2023) Molecular biomarkers for the diagnosis, prognosis, and pharmacodynamics of spinal muscular atrophy. J Clin Med 12:5060. https:\/\/doi.org\/10.3390\/jcm12155060","journal-title":"J Clin Med"},{"key":"13314_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-023-00413-6","volume":"18","author":"M Garofalo","year":"2023","unstructured":"Garofalo M, Bonanno S, Marcuzzo S, Pandini C, Scarian E, Dragoni F, Di Gerlando R, Bordoni M, Parravicini S, Gellera C, Masson R, Dosi C, Zanin R, Pansarasa O, Cereda C, Berardinelli A, Gagliardi S (2023) Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen. Biol Direct 18:57. https:\/\/doi.org\/10.1186\/s13062-023-00413-6","journal-title":"Biol Direct"},{"key":"13314_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/cells12192374","volume":"12","author":"M Leo","year":"2023","unstructured":"Leo M, Schmitt LI, Mairinger F, Roos A, Hansmann C, Hezel S, Skuljec J, Pul R, Schara-Schmidt U, Kleinschnitz C, Hagenacker T (2023) Analysis of free circulating messenger ribonucleic acids in serum samples from late-onset spinal muscular atrophy patients using nCounter NanoString technology. Cells 12:2374. https:\/\/doi.org\/10.3390\/cells12192374","journal-title":"Cells"},{"key":"13314_CR165","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00018-024-05426-6","volume":"81","author":"C Panicucci","year":"2024","unstructured":"Panicucci C, Sahin E, Bartolucci M, Casalini S, Brolatti N, Pedemonte M, Baratto S, Pintus S, Principi E, D\u2019Amico A, Pane M, Sframeli M, Messina S, Albamonte E, Sansone VA, Mercuri E, Bertini E, Sezerman U, Petretto A, Bruno C (2024) Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy. Cell Mol Life Sci 81:393. https:\/\/doi.org\/10.1007\/s00018-024-05426-6","journal-title":"Cell Mol Life Sci"},{"key":"13314_CR166","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00018-023-04885-7","volume":"80","author":"I Faravelli","year":"2023","unstructured":"Faravelli I, Gagliardi D, Abati E, Meneri M, Ongaro J, Magri F, Parente V, Petrozzi L, Ricci G, Far\u00e8 F, Garrone G, Fontana M, Caruso D, Siciliano G, Comi GP, Govoni A, Corti S, Ottoboni L (2023) Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study. Cell Mol Life Sci 80:241. https:\/\/doi.org\/10.1007\/s00018-023-04885-7","journal-title":"Cell Mol Life Sci"},{"key":"13314_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-025-00513-0","author":"DC Pant","year":"2025","unstructured":"Pant DC, Verma S (2025) Identifying novel response markers for spinal muscular atrophy revealed by targeted proteomics following gene therapy. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-025-00513-0","journal-title":"Gene Ther"},{"key":"13314_CR168","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14718","volume":"30","author":"M Lu","year":"2024","unstructured":"Lu M, Wang X, Sun N, Huang S, Yang L, Li D (2024) Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type II and type III. CNS Neurosci Ther 30:e14718. https:\/\/doi.org\/10.1111\/cns.14718","journal-title":"CNS Neurosci Ther"},{"key":"13314_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212123","volume":"25","author":"A Saffari","year":"2024","unstructured":"Saffari A, Niesert M, Cannet C, Blaschek A, Hahn A, Johannsen J, Kockaya M, K\u00f6lbel H, Hoffmann GF, Claus P, K\u00f6lker S, M\u00fcller-Felber W, Roos A, Schara-Schmidt U, Trefz FK, Vill K, Wick W, Weiler M, Okun JG, Ziegler A (2024) Identification of biochemical determinants for diagnosis and prediction of severity in 5q spinal muscular atrophy using 1H-nuclear magnetic resonance metabolic profiling in patient-derived biofluids. Int J Mol Sci 25:12123. https:\/\/doi.org\/10.3390\/ijms252212123","journal-title":"Int J Mol Sci"},{"key":"13314_CR170","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/biom12101431","volume":"12","author":"F Errico","year":"2022","unstructured":"Errico F, Marino C, Grimaldi M, Nuzzo T, Bassareo V, Valsecchi V, Panicucci C, Di Schiavi E, Mazza T, Bruno C, D\u2019Amico A, Carta M, D\u2019Ursi AM, Bertini E, Pellizzoni L, Usiello A (2022) Nusinersen induces disease-severity-specific neurometabolic effects in spinal muscular atrophy. Biomolecules 12:1431. https:\/\/doi.org\/10.3390\/biom12101431","journal-title":"Biomolecules"},{"key":"13314_CR171","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1212\/WNL.0b013e3182604395","volume":"79","author":"T Srivastava","year":"2012","unstructured":"Srivastava T, Darras BT, Wu JS, Rutkove SB (2012) Machine learning algorithms to classify spinal muscular atrophy subtypes. Neurology 79:358\u2013364. https:\/\/doi.org\/10.1212\/WNL.0b013e3182604395","journal-title":"Neurology"},{"key":"13314_CR172","doi-asserted-by":"publisher","first-page":"11838","DOI":"10.1038\/s41598-024-62720-w","volume":"14","author":"TL Vu-Han","year":"2024","unstructured":"Vu-Han TL, Schettino RB, Wei\u00df C, Perka C, Winkler T, Sunkara V, Pumberger M (2024) An interpretable data-driven prediction model to anticipate scoliosis in spinal muscular atrophy in the era of (gene-) therapies. Sci Rep 14:11838. https:\/\/doi.org\/10.1038\/s41598-024-62720-w","journal-title":"Sci Rep"},{"key":"13314_CR173","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00431-022-04470-3","volume":"181","author":"M Pane","year":"2022","unstructured":"Pane M, Donati MA, Cutrona C, De Sanctis R, Pirinu M, Coratti G, Ricci M, Palermo C, Berti B, Leone D, Ticci C, Sacchini M, Cerboneschi M, Capasso A, Cicala G, Pera MC, Bravetti C, Abiusi E, Vaisfeld A, Vento G, Tiziano FD, Mercuri E (2022) Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. Eur J Pediatr 181:2821\u20132829. https:\/\/doi.org\/10.1007\/s00431-022-04470-3","journal-title":"Eur J Pediatr"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13314-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:02:31Z","timestamp":1775847751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13314-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":173,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13314"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13314-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SC served in SAB for Biogen, Novartis, Roche. LO reports no competing interests in relation to this paper. VS participated in SAB for Roche, Biogen, Novartis, and Sarepta. Her work has involved clinical trials and studies related to neuromuscular conditions. No competing interests related to this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"605"}}